Peptichemio in multiple myeloma. (Preliminary results)

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

European journal of haematology·2026

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

Clinical and experimental medicine·2025

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Journal of cancer research and clinical oncology·2025

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

Journal of bone oncology·2025

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.

Cancer medicine·2024

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Haematologica·2026

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Haematologica·2026

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Haematologica·2026

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Haematologica·2026

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Haematologica·2026

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Haematologica·2026

[Rapidly Progressive Organizing Pneumonia Associated with Nontuberculous Mycobacterial Infection: A Diagnostic Challenge].

Journal of the Korean Society of Radiology·2026

3D biomimetic microgel platform for multiple myeloma: Approaching tumor microenvironment on cell lines and patient-derived cells.

Materials today. Bio·2026

Nontuberculous Mycobacterial Infections at a National Cancer Institute-Designated Comprehensive Cancer Center in Florida.

Open forum infectious diseases·2026

Correction: Chronic osteomyelitis diagnosis using MRI: optimising radiomics models through multi-level region of interest extensions.

Frontiers in bioengineering and biotechnology·2026

Identification of a key water molecule involved in the macrophage migration inhibitory factor-catalyzed tautomerization of para-hydroxyphenylpyruvate using neutron crystallography.

Protein science : a publication of the Protein Society·2026

Targeting the IL-17C-M2 macrophage axis ameliorates fibrosis in endometriosis through MAPK/ERK signaling.

Journal of translational medicine·2026

Related Experiment Videos

Peptichemio in multiple myeloma. (Preliminary results)

Related Concept Videos

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

[Rapidly Progressive Organizing Pneumonia Associated with Nontuberculous Mycobacterial Infection: A Diagnostic Challenge].

3D biomimetic microgel platform for multiple myeloma: Approaching tumor microenvironment on cell lines and patient-derived cells.

Nontuberculous Mycobacterial Infections at a National Cancer Institute-Designated Comprehensive Cancer Center in Florida.

Correction: Chronic osteomyelitis diagnosis using MRI: optimising radiomics models through multi-level region of interest extensions.

Identification of a key water molecule involved in the macrophage migration inhibitory factor-catalyzed tautomerization of para-hydroxyphenylpyruvate using neutron crystallography.

Targeting the IL-17C-M2 macrophage axis ameliorates fibrosis in endometriosis through MAPK/ERK signaling.

Related Experiment Videos

Peptichemio in multiple myeloma. (Preliminary results)

Related Concept Videos

Related Articles